FlexCare Clinical Research, LLC (FlexCare) announced formation of the company, a clinical service provider focused on providing study visits in the home or alternate site settings via a network of clinicians.
FlexCare was created to meet demand from the biopharmaceutical industry to accelerate clinical trials and streamline study processes. Traditionally, clinical trials are conducted at investigative sites such as hospitals or clinics, where subjects are required to travel for protocol-related tests and assessments throughout the duration of the study. Consequently, for decades, subject recruitment and retention have become challenges in the timely completion of clinical trials. FlexCare’s service model is designed to take the study to the subject, where protocol activities can be conducted in their home or at other alternate locations. FlexCare’s services also hope to benefit pediatric or geriatric subjects, students and working adults who find participation in traditional studies inconvenient.
FlexCare centrally manages study visits that are conducted by its network of clinicians. Services offered by FlexCare include study drug administration, blood draws and other biologic sample collections, clinical assessments, questionnaires and training at the subject’s home or other convenient location.
With the company’s launch, Gail Adinamis was named to the role of chief executive officer. Concurrent with Adinamis’ appointment, Dr. Gizelle Baker was named chief operating officer and Dr. Debbie Wilkerson, chief scientific officer.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.